385 related articles for article (PubMed ID: 23745738)
1. Preclinical models of antipsychotic drug action.
Moreno JL; González-Maeso J
Int J Neuropsychopharmacol; 2013 Nov; 16(10):2131-44. PubMed ID: 23745738
[TBL] [Abstract][Full Text] [Related]
2. Serotonergic hallucinogens as translational models relevant to schizophrenia.
Halberstadt AL; Geyer MA
Int J Neuropsychopharmacol; 2013 Nov; 16(10):2165-80. PubMed ID: 23942028
[TBL] [Abstract][Full Text] [Related]
3. Psychedelics and schizophrenia.
González-Maeso J; Sealfon SC
Trends Neurosci; 2009 Apr; 32(4):225-32. PubMed ID: 19269047
[TBL] [Abstract][Full Text] [Related]
4. Disruption of thalamocortical activity in schizophrenia models: relevance to antipsychotic drug action.
Celada P; Lladó-Pelfort L; Santana N; Kargieman L; Troyano-Rodriguez E; Riga MS; Artigas F
Int J Neuropsychopharmacol; 2013 Nov; 16(10):2145-63. PubMed ID: 23809188
[TBL] [Abstract][Full Text] [Related]
5. Preclinical models of schizophrenia.
Frazer A; Artigas F
Int J Neuropsychopharmacol; 2013 Nov; 16(10):2129. PubMed ID: 24369034
[No Abstract] [Full Text] [Related]
6. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.
Meltzer HY; Rajagopal L; Huang M; Oyamada Y; Kwon S; Horiguchi M
Int J Neuropsychopharmacol; 2013 Nov; 16(10):2181-94. PubMed ID: 24099265
[TBL] [Abstract][Full Text] [Related]
7. Role of mGlu2 in the 5-HT
Hideshima KS; Hojati A; Saunders JM; On DM; de la Fuente Revenga M; Shin JM; Sánchez-González A; Dunn CM; Pais AB; Pais AC; Miles MF; Wolstenholme JT; González-Maeso J
Psychopharmacology (Berl); 2018 Nov; 235(11):3149-3165. PubMed ID: 30209534
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors.
Rodrigues da Silva N; Gomes FV; Sonego AB; Silva NRD; Guimarães FS
Pharmacol Res; 2020 Jun; 156():104749. PubMed ID: 32151683
[TBL] [Abstract][Full Text] [Related]
9. An animal model of schizophrenia based on chronic LSD administration: old idea, new results.
Marona-Lewicka D; Nichols CD; Nichols DE
Neuropharmacology; 2011 Sep; 61(3):503-12. PubMed ID: 21352832
[TBL] [Abstract][Full Text] [Related]
10. The reversal of cognitive, but not negative or positive symptoms of schizophrenia, by the mGlu₂/₃ receptor agonist, LY379268, is 5-HT₁A dependent.
Wierońska JM; Sławińska A; Stachowicz K; Łasoń-Tyburkiewicz M; Gruca P; Papp M; Pilc A
Behav Brain Res; 2013 Nov; 256():298-304. PubMed ID: 23948211
[TBL] [Abstract][Full Text] [Related]
11. The role of group I metabotropic glutamate receptors in schizophrenia.
Pietraszek M; Nagel J; Gravius A; Schäfer D; Danysz W
Amino Acids; 2007 Feb; 32(2):173-8. PubMed ID: 16699816
[TBL] [Abstract][Full Text] [Related]
12. ErbB signaling antagonist ameliorates behavioral deficit induced by phencyclidine (PCP) in mice, without affecting metabolic syndrome markers.
Tadmor H; Golani I; Doron R; Kremer I; Shamir A
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Mar; 82():322-331. PubMed ID: 28818421
[TBL] [Abstract][Full Text] [Related]
13. RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia.
Rajagopal L; Kwon S; Huang M; Michael E; Bhat L; Cantillon M; Meltzer HY
Behav Brain Res; 2017 Aug; 332():180-199. PubMed ID: 28373127
[TBL] [Abstract][Full Text] [Related]
14. Chronic infusion of PCP via osmotic mini-pumps: a new rodent model of cognitive deficit in schizophrenia characterized by impaired attentional set-shifting (ID/ED) performance.
Pedersen CS; Goetghebeur P; Dias R
J Neurosci Methods; 2009 Dec; 185(1):66-9. PubMed ID: 19761795
[TBL] [Abstract][Full Text] [Related]
15. Receptor pair for schizophrenia.
Sealfon SC; González-Maeso J
Pediatr Res; 2008 Jul; 64(1):1. PubMed ID: 18574404
[No Abstract] [Full Text] [Related]
16. PCP-induced deficits in murine nest building activity: employment of an ethological rodent behavior to mimic negative-like symptoms of schizophrenia.
Pedersen CS; Sørensen DB; Parachikova AI; Plath N
Behav Brain Res; 2014 Oct; 273():63-72. PubMed ID: 25064467
[TBL] [Abstract][Full Text] [Related]
17. Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.
Schlumberger C; Schäfer D; Barberi C; Morè L; Nagel J; Pietraszek M; Schmidt WJ; Danysz W
Behav Pharmacol; 2009 Feb; 20(1):56-66. PubMed ID: 19179851
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action?
Ghose S; Gleason KA; Potts BW; Lewis-Amezcua K; Tamminga CA
Am J Psychiatry; 2009 Jul; 166(7):812-20. PubMed ID: 19487395
[TBL] [Abstract][Full Text] [Related]
19. Effects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophrenia.
Zuo D; Bzdega T; Olszewski RT; Moffett JR; Neale JH
J Biol Chem; 2012 Jun; 287(26):21773-82. PubMed ID: 22570482
[TBL] [Abstract][Full Text] [Related]
20. Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans.
Moghaddam B; Krystal JH
Schizophr Bull; 2012 Sep; 38(5):942-9. PubMed ID: 22899397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
